Investor Presentaiton

35 55 INO-5151 Phase 2 Prostate Cancer Combination Study TRIAL: INO-5151 (encoding tumor-associated antigens: PSA, PSMA) Phase 2 study (PORTER) for metastatic castration-resistant prostate cancer x45 Three cohort, 45-patient platform study, INO-5151 in Cohort C Cohort C-15 patients INO-5151 (DNA immunotherapy) CDX-301 (FLT3 ligand) from Celldex Therapeutics Nivolumab (anti-PD-1) from Bristol-Myers Squibb PICI/CRI will fund & execute the clinical study PICI PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY CANCER RESEARCH INSTITUTE INOVIO POWERING DNA MEDICINES

View entire presentation